- Home
- HYPR vs COEP Comparison
HYPR vs COEP Comparison
Compare HYPR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | COEP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HYPR | COEP |
|---|---|---|
| Price | $1.07 | $15.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.28 | N/A |
| AVG Volume (30 Days) | ★ 614.7K | 71.0K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,591,000.00 | $500,996.00 |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $35.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $2.31 |
| 52 Week High | $2.22 | $21.41 |
Technical Indicators
Market Signals| Indicator | HYPR | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 47.72 |
| Support Level | $0.85 | $15.40 |
| Resistance Level | $1.18 | $16.80 |
| Average True Range (ATR) | 0.09 | 1.57 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 68.37 | 20.64 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.